APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immune Globulin Intravenous

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Immune Globulin Intravenous Market Outlook and Growth Opportunities 2026

22 December 2025194 pages

Choose your research edition.

Industry ResearchHuman Immune Globulin Intravenous Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immune Globulin Intravenous Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Human Immune Globulin Intravenous Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immune Globulin Intravenous Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immune Globulin Intravenous Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Immune Globulin Intravenous market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Immune Globulin Intravenous is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Immune Globulin Intravenous is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Immune Globulin Intravenous is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Immune Globulin Intravenous market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Immune Globulin Intravenous market include Takeda, Sichuan Yuanda Shuyang, Shanghai RAAS, Hualan Bio, Octapharma, LFB Group, Kedrion, Grifols and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Immune Globulin Intravenous market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Immune Globulin Intravenous and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Immune Globulin Intravenous sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Immune Globulin Intravenous market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Immune Globulin Intravenous Segment by Company

Takeda

Sichuan Yuanda Shuyang

Shanghai RAAS

Hualan Bio

Octapharma

LFB Group

Kedrion

Grifols

CSL

CNBG

CBPO

BPL

Biotest

Human Immune Globulin Intravenous Segment by Type

IVIg Liquid

IVIg Powder

Human Immune Globulin Intravenous Segment by Application

Autoimmune Disease

Immunodeficiency

Acute Infection

Human Immune Globulin Intravenous Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Immune Globulin Intravenous status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Immune Globulin Intravenous market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Immune Globulin Intravenous significant trends, drivers, influence factors in global and regions.

6. To analyze Human Immune Globulin Intravenous competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immune Globulin Intravenous market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immune Globulin Intravenous and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immune Globulin Intravenous.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Immune Globulin Intravenous market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Immune Globulin Intravenous industry.

Chapter 3: Detailed analysis of Human Immune Globulin Intravenous manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Immune Globulin Intravenous in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Immune Globulin Intravenous in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Immune Globulin Intravenous Industry Trends Table 2. Human Immune Globulin Intravenous Industry Drivers Table 3. Human Immune Globulin Intravenous Industry Opportunities and Challenges Table 4. Human Immune Globulin Intravenous Industry Restraints Table 5. Global Human Immune Globulin Intravenous Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Immune Globulin Intravenous Revenue Share by Company (2021-2026) Table 7. Global Human Immune Globulin Intravenous Sales Volume by Company (units) & (2021-2026) Table 8. Global Human Immune Globulin Intravenous Sales Volume Share by Company (2021-2026) Table 9. Global Human Immune Globulin Intravenous Average Price (US$/unit) of Company (2021-2026) Table 10. Global Human Immune Globulin Intravenous Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Immune Globulin Intravenous Key Company Manufacturing Base & Headquarters Table 12. Global Human Immune Globulin Intravenous Company, Product Type & Application Table 13. Global Human Immune Globulin Intravenous Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Immune Globulin Intravenous by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of IVIg Liquid Table 18. Significant Companies of IVIg Powder Table 19. Global Human Immune Globulin Intravenous Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 20. Global Human Immune Globulin Intravenous Sales Volume by Type (2021-2026) & (units) Table 21. Global Human Immune Globulin Intravenous Sales Volume by Type (2027-2032) & (units) Table 22. Global Human Immune Globulin Intravenous Sales Volume Share by Type (2021-2026) Table 23. Global Human Immune Globulin Intravenous Sales Volume Share by Type (2027-2032) Table 24. Global Human Immune Globulin Intravenous Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Immune Globulin Intravenous Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Human Immune Globulin Intravenous Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Human Immune Globulin Intravenous Sales Value Share by Type (2021-2026) Table 28. Global Human Immune Globulin Intravenous Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Autoimmune Disease Table 30. Significant Companies of Immunodeficiency Table 31. Significant Companies of Acute Infection Table 32. Global Human Immune Globulin Intravenous Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 33. Global Human Immune Globulin Intravenous Sales Volume by Application (2021-2026) & (units) Table 34. Global Human Immune Globulin Intravenous Sales Volume by Application (2027-2032) & (units) Table 35. Global Human Immune Globulin Intravenous Sales Volume Share by Application (2021-2026) Table 36. Global Human Immune Globulin Intravenous Sales Volume Share by Application (2027-2032) Table 37. Global Human Immune Globulin Intravenous Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Human Immune Globulin Intravenous Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Human Immune Globulin Intravenous Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Human Immune Globulin Intravenous Sales Value Share by Application (2021-2026) Table 41. Global Human Immune Globulin Intravenous Sales Value Share by Application (2027-2032) Table 42. Global Human Immune Globulin Intravenous Sales by Region: 2021 VS 2025 VS 2032 (units) Table 43. Global Human Immune Globulin Intravenous Sales by Region (2021-2026) & (units) Table 44. Global Human Immune Globulin Intravenous Sales Market Share by Region (2021-2026) Table 45. Global Human Immune Globulin Intravenous Sales by Region (2027-2032) & (units) Table 46. Global Human Immune Globulin Intravenous Sales Market Share by Region (2027-2032) Table 47. Global Human Immune Globulin Intravenous Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Human Immune Globulin Intravenous Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Human Immune Globulin Intravenous Sales Value Share by Region (2021-2026) Table 50. Global Human Immune Globulin Intravenous Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Human Immune Globulin Intravenous Sales Value Share by Region (2027-2032) Table 52. Global Human Immune Globulin Intravenous Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Human Immune Globulin Intravenous Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Human Immune Globulin Intravenous Sales by Country: 2021 VS 2025 VS 2032 (units) Table 55. Global Human Immune Globulin Intravenous Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Human Immune Globulin Intravenous Sales by Country (2021-2026) & (units) Table 57. Global Human Immune Globulin Intravenous Sales Market Share by Country (2021-2026) Table 58. Global Human Immune Globulin Intravenous Sales by Country (2027-2032) & (units) Table 59. Global Human Immune Globulin Intravenous Sales Market Share by Country (2027-2032) Table 60. Global Human Immune Globulin Intravenous Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Human Immune Globulin Intravenous Sales Value Market Share by Country (2021-2026) Table 62. Global Human Immune Globulin Intravenous Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Human Immune Globulin Intravenous Sales Value Market Share by Country (2027-2032) Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Takeda Human Immune Globulin Intravenous Product Portfolio Table 68. Takeda Recent Development Table 69. Sichuan Yuanda Shuyang Company Information Table 70. Sichuan Yuanda Shuyang Business Overview Table 71. Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Product Portfolio Table 73. Sichuan Yuanda Shuyang Recent Development Table 74. Shanghai RAAS Company Information Table 75. Shanghai RAAS Business Overview Table 76. Shanghai RAAS Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Shanghai RAAS Human Immune Globulin Intravenous Product Portfolio Table 78. Shanghai RAAS Recent Development Table 79. Hualan Bio Company Information Table 80. Hualan Bio Business Overview Table 81. Hualan Bio Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Hualan Bio Human Immune Globulin Intravenous Product Portfolio Table 83. Hualan Bio Recent Development Table 84. Octapharma Company Information Table 85. Octapharma Business Overview Table 86. Octapharma Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Octapharma Human Immune Globulin Intravenous Product Portfolio Table 88. Octapharma Recent Development Table 89. LFB Group Company Information Table 90. LFB Group Business Overview Table 91. LFB Group Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. LFB Group Human Immune Globulin Intravenous Product Portfolio Table 93. LFB Group Recent Development Table 94. Kedrion Company Information Table 95. Kedrion Business Overview Table 96. Kedrion Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Kedrion Human Immune Globulin Intravenous Product Portfolio Table 98. Kedrion Recent Development Table 99. Grifols Company Information Table 100. Grifols Business Overview Table 101. Grifols Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Grifols Human Immune Globulin Intravenous Product Portfolio Table 103. Grifols Recent Development Table 104. CSL Company Information Table 105. CSL Business Overview Table 106. CSL Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. CSL Human Immune Globulin Intravenous Product Portfolio Table 108. CSL Recent Development Table 109. CNBG Company Information Table 110. CNBG Business Overview Table 111. CNBG Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. CNBG Human Immune Globulin Intravenous Product Portfolio Table 113. CNBG Recent Development Table 114. CBPO Company Information Table 115. CBPO Business Overview Table 116. CBPO Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. CBPO Human Immune Globulin Intravenous Product Portfolio Table 118. CBPO Recent Development Table 119. BPL Company Information Table 120. BPL Business Overview Table 121. BPL Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. BPL Human Immune Globulin Intravenous Product Portfolio Table 123. BPL Recent Development Table 124. Biotest Company Information Table 125. Biotest Business Overview Table 126. Biotest Human Immune Globulin Intravenous Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Biotest Human Immune Globulin Intravenous Product Portfolio Table 128. Biotest Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Human Immune Globulin Intravenous Distributors List Table 132. Human Immune Globulin Intravenous Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Human Immune Globulin Intravenous Product Image Figure 2. Global Human Immune Globulin Intravenous Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immune Globulin Intravenous Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Immune Globulin Intravenous Sales (2021-2032) & (units) Figure 5. Global Human Immune Globulin Intravenous Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Human Immune Globulin Intravenous Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. IVIg Liquid Image Figure 10. IVIg Powder Image Figure 11. Global Human Immune Globulin Intravenous Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 12. Global Human Immune Globulin Intravenous Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Human Immune Globulin Intravenous Sales Volume Share by Type (2021-2032) Figure 14. Global Human Immune Globulin Intravenous Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Human Immune Globulin Intravenous Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Human Immune Globulin Intravenous Sales Value Share by Type (2021-2032) Figure 17. Autoimmune Disease Image Figure 18. Immunodeficiency Image Figure 19. Acute Infection Image Figure 20. Global Human Immune Globulin Intravenous Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 21. Global Human Immune Globulin Intravenous Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Human Immune Globulin Intravenous Sales Volume Share by Application (2021-2032) Figure 23. Global Human Immune Globulin Intravenous Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Human Immune Globulin Intravenous Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Human Immune Globulin Intravenous Sales Value Share by Application (2021-2032) Figure 26. Global Human Immune Globulin Intravenous Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 27. Global Human Immune Globulin Intravenous Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Human Immune Globulin Intravenous Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Human Immune Globulin Intravenous Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Human Immune Globulin Intravenous Sales Value (2021-2032) & (US$ Million) Figure 31. North America Human Immune Globulin Intravenous Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Human Immune Globulin Intravenous Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Human Immune Globulin Intravenous Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Human Immune Globulin Intravenous Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Human Immune Globulin Intravenous Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Human Immune Globulin Intravenous Sales Value (2021-2032) & (US$ Million) Figure 37. South America Human Immune Globulin Intravenous Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Human Immune Globulin Intravenous Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Human Immune Globulin Intravenous Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Human Immune Globulin Intravenous Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Human Immune Globulin Intravenous Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • IVIg Liquid
  • IVIg Powder
Applications
  • Autoimmune Disease
  • Immunodeficiency
  • Acute Infection
Companies covered
  • Takeda
  • Sichuan Yuanda Shuyang
  • Shanghai RAAS
  • Hualan Bio
  • Octapharma
  • LFB Group
  • Kedrion
  • Grifols
  • CSL
  • CNBG
  • CBPO
  • BPL
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Immune Globulin Intravenous Sales Value (2021-2032)
  4. 1.2.2 Global Human Immune Globulin Intravenous Sales Volume (2021-2032)
  5. 1.2.3 Global Human Immune Globulin Intravenous Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Immune Globulin Intravenous Market Dynamics
  1. 2.1 Human Immune Globulin Intravenous Industry Trends
  2. 2.2 Human Immune Globulin Intravenous Industry Drivers
  3. 2.3 Human Immune Globulin Intravenous Industry Opportunities and Challenges
  4. 2.4 Human Immune Globulin Intravenous Industry Restraints
3 Human Immune Globulin Intravenous Market by Company
  1. 3.1 Global Human Immune Globulin Intravenous Company Revenue Ranking in 2025
  2. 3.2 Global Human Immune Globulin Intravenous Revenue by Company (2021-2026)
  3. 3.3 Global Human Immune Globulin Intravenous Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Immune Globulin Intravenous Average Price by Company (2021-2026)
  5. 3.5 Global Human Immune Globulin Intravenous Company Ranking (2024-2026)
  6. 3.6 Global Human Immune Globulin Intravenous Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Immune Globulin Intravenous Company Product Type and Application
  8. 3.8 Global Human Immune Globulin Intravenous Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Immune Globulin Intravenous Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Immune Globulin Intravenous Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Immune Globulin Intravenous Market by Type
  1. 4.1 Human Immune Globulin Intravenous Type Introduction
  2. 4.1.1 IVIg Liquid
  3. 4.1.2 IVIg Powder
  4. 4.2 Global Human Immune Globulin Intravenous Sales Volume by Type
  5. 4.2.1 Global Human Immune Globulin Intravenous Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Immune Globulin Intravenous Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Human Immune Globulin Intravenous Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Human Immune Globulin Intravenous Sales Value by Type
  9. 4.3.1 Global Human Immune Globulin Intravenous Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Immune Globulin Intravenous Sales Value by Type (2021-2032)
  11. 4.3.3 Global Human Immune Globulin Intravenous Sales Value Share by Type (2021-2032)
5 Human Immune Globulin Intravenous Market by Application
  1. 5.1 Human Immune Globulin Intravenous Application Introduction
  2. 5.1.1 Autoimmune Disease
  3. 5.1.2 Immunodeficiency
  4. 5.1.3 Acute Infection
  5. 5.2 Global Human Immune Globulin Intravenous Sales Volume by Application
  6. 5.2.1 Global Human Immune Globulin Intravenous Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Immune Globulin Intravenous Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Human Immune Globulin Intravenous Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Human Immune Globulin Intravenous Sales Value by Application
  10. 5.3.1 Global Human Immune Globulin Intravenous Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Immune Globulin Intravenous Sales Value by Application (2021-2032)
  12. 5.3.3 Global Human Immune Globulin Intravenous Sales Value Share by Application (2021-2032)
6 Human Immune Globulin Intravenous Regional Sales and Value Analysis
  1. 6.1 Global Human Immune Globulin Intravenous Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Immune Globulin Intravenous Sales by Region (2021-2032)
  3. 6.2.1 Global Human Immune Globulin Intravenous Sales by Region: 2021-2026
  4. 6.2.2 Global Human Immune Globulin Intravenous Sales by Region (2027-2032)
  5. 6.3 Global Human Immune Globulin Intravenous Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Immune Globulin Intravenous Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Immune Globulin Intravenous Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Immune Globulin Intravenous Sales Value by Region (2027-2032)
  9. 6.5 Global Human Immune Globulin Intravenous Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Immune Globulin Intravenous Sales Value (2021-2032)
  12. 6.6.2 North America Human Immune Globulin Intravenous Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Immune Globulin Intravenous Sales Value (2021-2032)
  15. 6.7.2 Europe Human Immune Globulin Intravenous Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Immune Globulin Intravenous Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Immune Globulin Intravenous Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Immune Globulin Intravenous Sales Value (2021-2032)
  21. 6.9.2 South America Human Immune Globulin Intravenous Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Immune Globulin Intravenous Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Immune Globulin Intravenous Sales Value Share by Country, 2025 VS 2032
7 Human Immune Globulin Intravenous Country-level Sales and Value Analysis
  1. 7.1 Global Human Immune Globulin Intravenous Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Immune Globulin Intravenous Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Immune Globulin Intravenous Sales by Country (2021-2032)
  4. 7.3.1 Global Human Immune Globulin Intravenous Sales by Country (2021-2026)
  5. 7.3.2 Global Human Immune Globulin Intravenous Sales by Country (2027-2032)
  6. 7.4 Global Human Immune Globulin Intravenous Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Immune Globulin Intravenous Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Immune Globulin Intravenous Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Immune Globulin Intravenous Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Immune Globulin Intravenous Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Immune Globulin Intravenous Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Human Immune Globulin Intravenous Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sichuan Yuanda Shuyang
  8. 8.2.1 Sichuan Yuanda Shuyang Company Information
  9. 8.2.2 Sichuan Yuanda Shuyang Business Overview
  10. 8.2.3 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Product Portfolio
  12. 8.2.5 Sichuan Yuanda Shuyang Recent Developments
  13. 8.3 Shanghai RAAS
  14. 8.3.1 Shanghai RAAS Company Information
  15. 8.3.2 Shanghai RAAS Business Overview
  16. 8.3.3 Shanghai RAAS Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai RAAS Human Immune Globulin Intravenous Product Portfolio
  18. 8.3.5 Shanghai RAAS Recent Developments
  19. 8.4 Hualan Bio
  20. 8.4.1 Hualan Bio Company Information
  21. 8.4.2 Hualan Bio Business Overview
  22. 8.4.3 Hualan Bio Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hualan Bio Human Immune Globulin Intravenous Product Portfolio
  24. 8.4.5 Hualan Bio Recent Developments
  25. 8.5 Octapharma
  26. 8.5.1 Octapharma Company Information
  27. 8.5.2 Octapharma Business Overview
  28. 8.5.3 Octapharma Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Octapharma Human Immune Globulin Intravenous Product Portfolio
  30. 8.5.5 Octapharma Recent Developments
  31. 8.6 LFB Group
  32. 8.6.1 LFB Group Company Information
  33. 8.6.2 LFB Group Business Overview
  34. 8.6.3 LFB Group Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 LFB Group Human Immune Globulin Intravenous Product Portfolio
  36. 8.6.5 LFB Group Recent Developments
  37. 8.7 Kedrion
  38. 8.7.1 Kedrion Company Information
  39. 8.7.2 Kedrion Business Overview
  40. 8.7.3 Kedrion Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Kedrion Human Immune Globulin Intravenous Product Portfolio
  42. 8.7.5 Kedrion Recent Developments
  43. 8.8 Grifols
  44. 8.8.1 Grifols Company Information
  45. 8.8.2 Grifols Business Overview
  46. 8.8.3 Grifols Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Grifols Human Immune Globulin Intravenous Product Portfolio
  48. 8.8.5 Grifols Recent Developments
  49. 8.9 CSL
  50. 8.9.1 CSL Company Information
  51. 8.9.2 CSL Business Overview
  52. 8.9.3 CSL Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CSL Human Immune Globulin Intravenous Product Portfolio
  54. 8.9.5 CSL Recent Developments
  55. 8.10 CNBG
  56. 8.10.1 CNBG Company Information
  57. 8.10.2 CNBG Business Overview
  58. 8.10.3 CNBG Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 CNBG Human Immune Globulin Intravenous Product Portfolio
  60. 8.10.5 CNBG Recent Developments
  61. 8.11 CBPO
  62. 8.11.1 CBPO Company Information
  63. 8.11.2 CBPO Business Overview
  64. 8.11.3 CBPO Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 CBPO Human Immune Globulin Intravenous Product Portfolio
  66. 8.11.5 CBPO Recent Developments
  67. 8.12 BPL
  68. 8.12.1 BPL Company Information
  69. 8.12.2 BPL Business Overview
  70. 8.12.3 BPL Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 BPL Human Immune Globulin Intravenous Product Portfolio
  72. 8.12.5 BPL Recent Developments
  73. 8.13 Biotest
  74. 8.13.1 Biotest Company Information
  75. 8.13.2 Biotest Business Overview
  76. 8.13.3 Biotest Human Immune Globulin Intravenous Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Biotest Human Immune Globulin Intravenous Product Portfolio
  78. 8.13.5 Biotest Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Immune Globulin Intravenous Value Chain Analysis
  2. 9.1.1 Human Immune Globulin Intravenous Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Immune Globulin Intravenous Sales Mode & Process
  6. 9.2 Human Immune Globulin Intravenous Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Immune Globulin Intravenous Distributors
  9. 9.2.3 Human Immune Globulin Intravenous Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst